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ABSTRACT
Background To assess whether, in the real world of
three early arthritis clinics, early referral could allow the
best outcome, ie, remission, to be reached, and whether
reaching the outcome was more dependent on therapy
than on disease duration or vice versa.
Methods 1795 patients with early arthritis (symptom
duration ≤12 months) were entered into a prospective
follow-up study. 711 patients (39.6%) were diagnosed
with rheumatoid arthritis (RA). Each RA patient was
treated according to the local algorithm, in three tertiary
referral centres (representing a small province, a medium
sized province and a metropolitan area, respectively).
Remission, deﬁned using the disease activity score in 28
joints (DAS28 <2.6) and American College of
Rheumatology (ACR) criteria, was the major outcome
evaluated at the 12-month follow-up.
Results DAS28 remission was achieved in 34.3% (range
19.5–49%) of RA patients and ACR remission in 15.2%
(range 8.5–20.6%). At the multivariate logistic regression
analysis only two variables emerged as predictors of the
major outcome: being in very early rheumatoid arthritis
(VERA; less than 12 weeks symptom duration at the time
of ﬁrst treatment) and being on disease-modifying
antirheumatic drugs (DMARD) within 3 months from
disease onset. Among RA patients in remission, only
10% of VERA subjects received an anti-TNF blocker
compared with 32.2% of non-VERA patients (p=0.002,
OR 0.23, 95% CI 0.09 to 0.64).
Conclusions In a real-world setting, the 12 weeks
disease duration and an early intervention with DMARD
represent the most signiﬁcant opportunities to reach the
major outcome, ie, remission of RA. Moreover, VERA
represents a window of opportunity in terms of cost
saving.
INTRODUCTION
The early identiﬁcation of rheumatoid arthritis (RA)
represents the crucial step for controlling the pro-
gression of the disease. The new deal in rheumatol-
ogy is early diagnosis and treatment in order to
reach the major outcome, ie, remission, quickly RA.
In 1970 Jacoby et al,1 reporting on the outcome of
RAwith early disease, showed that 62 patients pre-
senting with symptom duration less than 3 months
had a signiﬁcantly better outcome than 38 patients
referred later. Therefore, already in the 1970s, there
were data supporting the importance of an early
diagnosis and an early therapeutic intervention.
Over the past 10 years data have accumulated,
clearly showing in at least four different clinical
therapeutic settings, that treating a RA patient
within the ﬁrst 12–16 weeks from symptom onset
can really lead to a clinically meaningful different
outcome. In 2001 Lard et al,2 when treating patients
very rapidly after the ﬁrst visit (within 15 days)
compared with a slower intervention (4 months),
showed that the radiographic progression in the
rapid intervention subset was ﬂat after the ﬁrst
6 months, whereas it progressed over time up to
24 months in the slower intervention arm. The
FinRACo trial3 showed that a delay of 16 weeks in
using disease-modifying antirheumatic drugs
(DMARD) could lead to a lower chance of reaching
remission. More recently, in the early arthritis clinics
in Leiden, it was shown that a short symptom dur-
ation and an earlier therapeutic intervention before
12 weeks was associated with a greater chance of
reaching drug-free remission.4 In our own experience,
12 weeks disease duration was the best predictive
factor for reaching disease activity score in 28 joints
(DAS28) and/or American College of Rheumatology
(ACR) remission, in a tight-aggressive therapeutic
approach to early RA.5 These data have been con-
ﬁrmed in another recent Dutch trial.6 Therefore,
both monocentric clinical cohorts and formal clinical
trials suggest that a window of opportunity to reach
the best outcome in RA really exists.
In 2007 (until 2009), the Italian Ministry of
Health supported an observational prospective lon-
gitudinal study in three Italian referral centres, all
with already active early arthritis clinics, in order to
observe the behaviour of the referral, the delay
before referral, through whom the referral occurred
(general practitioners (GPs), other specialists or
direct patient call), and the outcome of an early
arthritis cohort referred to three different clinical
settings, a small province, an intermediate province
and a metropolitan area, using tight control strat-
egies. The main purpose was to understand the role
of an early referral on early RA outcome from diag-
nosis to therapy, to limit the costs related to this
disease. Data suggest that in a real-world setting
very early rheumatoid arthritis (VERA) represents
the best opportunity to reach the major outcome,
ie, full disease remission.
PATIENTS AND METHODS
All the patients referred to the early arthritis clinics
of three tertiary referral centres (Ancona–Università
Politecnica delle Marche, Pavia–Policlinico San
Matteo and Rome–Catholic University of the
Sacred Heart) between February 2007 and July 2009
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were collected. Entry criteria for the ﬁrst examination at the
early arthritis clinics were two or more swollen joints dating
from more than 2 weeks, but less than 12 months. All the sub-
jects fulﬁlling the 1987 classiﬁcation criteria for RA7 at the ﬁrst
visit were deﬁned as having early RA. All these early RA patients
also retrospectively met the new 2010 RA classiﬁcation criteria.8
Among subjects diagnosed as having early RA, those with
symptom duration of 3 months or less were deﬁned as VERA.
The type of referral was recorded (GP, orthopaedic, physiat-
rist, other specialists, others). Patients satisfying RA criteria
were collected in the database and followed up for at least
12 months. The follow-up study had the main aim of deter-
mining the major outcome of RA, and was restricted to the
patients having moderate–high RA activity at baseline (DAS28
>3.2), in order to highlight more stringent results.
Clinical (DAS28, health assessment questionnaire; HAQ) as well
as laboratory (acute phase reactants, IgM-rheumatoid factor,
anticitrullinated protein autoantibodies; ACPA) data were collected
over time. Seropositivity was deﬁned as previously described.9
The follow-up visits were made at weeks 0, 4, 12, 20, 24,
36 and 52.
Local ethics committees gave approval to the study protocol.
Clinical assessments
Clinical assessments included tender joint count (28 joints),
swollen joint count (28 joints), erythrocyte sedimentation
rate, C-reactive protein and morning stiffness duration.
Patient-reported outcomes included global assessments of pain
and general health on 100 mm visual analogue scales and HAQ
disability index.10 11
Workability was evaluated as described in a previous paper.12
Data on comorbidities were collected from the clinical history
of patients.
Study outcomes
The primary outcome was disease remission after 12 months
of follow-up, according to a very liberal therapeutic protocol
(according to local decisions), although strict and tight in
terms of assessment timing. For the evaluation of disease activ-
ity, we used two sets of criteria: DAS28 and the ACR criteria
for clinical remission in RA.13 Disease activity according to
DAS28 was interpreted as remission (DAS28 <2.6), low (2.6≤
DAS28 ≤3.2), moderate (3.2< DAS28 ≤5.1) and high (disease
activity score in 44 joints >5.1) activity.
Treatment
Therapy adjustments were protocolised to occur at every visit and,
based on the DAS28 assessment, treatment was intensiﬁed if the
predeﬁned targets (ie, DAS28 <2.6 for treatment with conven-
tional DMARD and DAS28 <3.2 for treatment with anti-tumour
necrosis factor alpha (TNFΑ) therapy) were not met.
At baseline, methotrexate was prescribed to all patients at an
initial dose of 15 mg/week, and it was increased, if required, up
to 25 mg/week. Once the patient, after 3 months of methotrex-
ate, had not reached the major outcome, the use of a DMARD
combination therapy or the addition of a biological anti-TNFα
agent was adopted, according to the local physician’s decision.
The three centres managed their patient treatment according to
their own decision, and no centralised protocol was used.
All patients gave their consent to enter into the study.
Radiology
Radiographs of hands and feet were taken at baseline and then
annually. Radiographs were evaluated in chronological order by
two observers (consensus score FS and EG) according to the
modiﬁed Sharp–van der Heijde score.14 Patients were classiﬁed
as ‘erosive’ if the erosion score was 1 or greater, and progression
was deﬁned once a new erosion occurred, compared with
baseline.
Statistical analysis
Categorical and quantitative variables were described as frequen-
cies, percentages, means and standard deviations (mean±SD).
The non-parametric Mann–Whitney U test was used to compare
the continuous variables. Categorical variables were analysed
using χ2 test or Fisher ’s exact test. Differences among centres
were analysed using the Kruskal–Wallis non-parametric test.
The signiﬁcance level was set at a p value less than 0.05.
A multivariate analysis was performed to examine which
factors were associated with DAS28 remission at the 12th month
of therapy in early RA patients with high–moderate disease activ-
ity at baseline. The variables related to ‘DAS28 remission at the
12th month of therapy’ with p≤0.10 in the univariate analysis
were included in a multivariate logistic regression model with
stepwise backward Wald elimination. The goodness of ﬁt of the
models was performed using the Hosmer–Lemeshow test.
Results are expressed as OR and 95% CI.
Data were analysed using SPSS 17.0 software for Windows
and Graph Pad Prism 5.0 software.
RESULTS
In the timeframe February 2007 to July 2009, 1795 patients with
early arthritis were assessed. The diagnosis of RA was made in
711 (39.6%) of evaluated patients. In the remaining 1084 sub-
jects, the following diagnosis was recorded: 550 (50.7%) undiffer-
entiated polyarthritis (UPA); 227 (20.9%) psoriatic arthritis; 115
(10.6%) spondyloentesoarthritis; 56 (5.1%) microcrystal-related
arthritis; 41 (3.8%) polymyalgia rheumatica; 22 (2.0%) reactive
arthritis; 19 (1.8%) undifferentiated connective tissue disease. In
54 subjects a speciﬁc diagnosis was not made.
In particular, of the 1795 total early arthritis cohort, 355
patients were referred to the early arthritis clinic in Pavia, 948
patients in Ancona and 482 in Rome.
Referral
In the early arthritis clinics of Pavia and Ancona 60.1% of
patients were referred by GPs, and the remaining by other spe-
cialists (20.4% by orthopaedics, 15.3% by physiatrists and 4.2%
by other specialists). In Rome, 45% of patients were referred to
the centre by physicians, while 55% of patients were directly
referred to the early arthritis clinic (through a call centre orga-
nised for this purpose, and made known by brochures, internet,
newspapers, TV).
UPA follow-up
All the subjects initially diagnosed with UPA were asked to
have a follow-up. After 12 months, 463 out of the 550 UPA
patients could be re-evaluated and 181 of them (39.1%) were
diagnosed with RA during a further 12 months follow-up.
RA follow-up
Among the 711 subjects initially diagnosed with RA, 74% were
women and the mean age was 54.7±12.4 years. Symptom dur-
ation at the time of RA diagnosis was 6.4±4.4 months and 148
(20.8%) subjects had VERA. The autoimmune phenotype was
found in 46.3% of the patients who were ACPA positive and in
51.6% who were rheumatoid factor positive, with important
differences among the three centres (table 1); 213 patients
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(29.9%) had at least one erosion in hands or feet. Moderate–
high disease activity (DAS28 >3.2) was present in 481 out of
the 711 RA patients (67.7%), all were available for a full clinical
and biological assessment at 12 months. This subgroup repre-
sented the cohort of completers-only analysis and the baseline
and 12-month characteristics were shown in table 2. The RA
patient group considered for the ﬁnal analysis differed from the
overall study cohort only by a higher DAS28 score and a higher
percentage of erosions at baseline.
Primary outcome
Considering the primary outcome, 165/481 (34.3%) RA
patients reached DAS28 remission at the 12-month follow-up.
The other categories of DAS28 activity at 12 months are sum-
marised in table 3. Seventy-three patients (15.2%) satisﬁed the
ACR remission criteria.
Medications
At the 12-month follow-up, 329/481 patients (68.4%) were
taking only DMARD (alone or in combination), whereas 152
(31.6%) were in combination therapy with TNFα blockers.
When we divided the RA patients based on the duration of
symptoms, we found that at the 12-month follow-up 95
(90.5%) patients with VERA were on DMARD only, while 10
(9.5%) were on biological drugs, compared with 279 (74.4%) and
96 (25.6%), respectively, of patients with symptom duration
greater than 3 months (p<0.001, OR 0.31, 95% CI0.15 to 0.61).
Moreover, among the 165 RA patients with disease remission
at the 12-month follow-up, only ﬁve of 50 VERA subjects
(10%) received an anti-TNF blocker, compared with 37/115
(32.2%) non-VERA patients (p=0.002, OR 0.23, 95% CI 0.09
to 0.64), suggesting that VERA requires a much lower use of
anti-TNF treatment to obtain disease control.
x-Rays
Of the 481 RA patients, 34.9% were erosive at baseline, 54.9%
were erosive at the 12th month. The mean annual progression
rate in the overall cohort, according to the modiﬁed Sharp–Van
der Heijde score, resulted in 5.8±6.2 units.
Comorbidities
Forty-one per cent of the patients had hypertension, 20% dia-
betes or thyroid diseases, 13% gastrointestinal diseases (gastritis
or colitis) and 4.9% central nervous system vascular diseases.
Disability
At baseline, HAQ values in the total RA cohort were 1.2±0.6
and decreased to 0.5±0.5 at 12 months of follow-up. Thirty
out of 481 patients (6.2%) maintained a HAQ of 1.5 or greater
after 1 year of therapy, despite the early treatment and diagno-
sis, indicating a moderate grade of disability. Considering
Table 1 Summary of the outcomes according to the three different
referral centres therapeutic approaches
EAC 1 EAC 2 EAC 3
p Value
1 vs 2
p Value
1 vs 3
p Value
2 vs 3
Sex, female 78.8% 68.6% 74.5% 0.02 0.8 0.3
Age, years 53.8±13.5 54.2±8.8 57.3±14.8 0.8 0.01 0.003
Disease duration
(months)
5.8±3.4 7.7±2.5 5.5±7.0 <0.001 0.001 <0.001
VERA
(≤12 weeks)
32.6% 1% 49.6% <0.001 0.01 <0.001
RF, % positive 67.8% 35.7% 51.2% <0.001 0.002 0.01
Anti-CCP, %
positive
68.6% 26.7% 38.2% <0.001 <0.001 0.1
DAS28 T0 5.4±1.3 5.8±0.7 5.0±1.1 <0.001 0.008 <0.001
DAS28 T12 2.8±1.3 4.0±1.3 3.0±1.1 <0.001 0.03 <0.001
HAQ T0 1.2±0.7 1.1±0.4 1.2±0.7 0.3 0.7 0.1
HAQ T12 0.4±0.5 0.7±0.4 0.4±0.6 <0.001 0.6 <0.001
DMARD only T12
(% of patients)
78.5% 58.6% 98.6% 0.006 <0.01 <0.001
Anti-TNF therapy
T12 (% of
patients)
31.5% 41.4% 1.4% 0.14 <0.001 <0.001
DAS28 remission
T12 (% of
patients)
49% 19.5% 36.6% <0.001 0.09 0.006
ACR remission
T12 (% of
patients)
20.6% 13.3% 8.5% 0.03 0.03 0.4
It can be seen that the approach was substantially different in the three early
arthritis clinics.
ACR, American College of Rheumatology; CCP, cyclic citrullinated protein; DAS28,
disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug;
EAC, early arthritis clinic; HAQ, health assessment questionnaire; RF, rheumatoid
factor; TNF, tumour necrosis factor; T0, baseline; T12, 12-month follow-up; VERA,
very early rheumatoid arthritis.
Table 2 Clinical and biological characteristics of the 481 early RA
patients who had a follow-up assessment of 12 months
Early RA patients n = 481 Baseline (T0) Follow-up (T12)
Gender: female, n (%) 358 (74.4) –
Age, years 54.4±12.0 –
Disease duration, months 6.4±3.3 –
VERA, n (%) 105 (21.8) –
DMARD only, n (%) – 329 (68.4)
Anti-TNF, n (%) – 152 (31.6)
Tender joint count (28 joints) 9.0±5.3 2.8±3.3
Swollen joint count (28 joints) 6.4±4.6 1.8±2.4
PhGA (0–100) 49.8±20.1 24.8±25.4
PGA (0–100) 60.6±19.8 27.0±23.3
VAS pain (0–100) 59.3±22.4 24.4±21.9
GH (0–100) 55.9±19.7 58.7±28.9
HAQ (0–3) 1.15±0.6 0.5±0.5
ESR, mm/1st h 38.9±21.9 23.2±15.5
CRP, mg/l 23.0±26.0 8.6±12.6
DAS28 5.4±1.1 3.4±1.4
Erosive patients, n (%) 168 (34.9) 264 (54.9)
CRP, C-reactive protein; DAS28, disease activity score in 28 joints; DMARD,
disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; GH,
general health; HAQ, health assessment questionnaire; TNF, tumour necrosis factor;
PGA, patient global assessment; PhGA, physician global assessment; RA,
rheumatoid arthritis; VAS, visual analogue scale; VERA, very early rheumatoid
arthritis.
Table 3 Major outcomes at the 12-month follow-up, following DAS28
cut-off points and ACR remission criteria, in the follow-up cohort
Disease activity status (T12) No (%) of patients (total 481)
ACR remission 73 (15.2%)
DAS28 status
Remission (≤2.6) 165 (34.3%)
Low disease activity (2.6–3.2) 88 (18.3%)
Moderate disease activity (3.2–5.1) 170 (35.3%)
High disease activity (>5.1) 58 (12.1%)
ACR, American College of Rheumatology; DAS28, disease activity score in 28 joints;
T12, 12-month follow-up.
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disease activity, 75% of patients in remission reached a HAQ
less than 0.5 (no disability) compared with 30.7% of patients
not reaching remission (p<0.001). Moreover, 62.7% of VERA
patients achieved a HAQ less than 0.5 at 1-year follow-up
compared with 41.3% of non-VERA subjects (p<0.001), regard-
less of achieving remission and despite similar HAQ values
at baseline (1.22±0.73 in VERA and 1.11±0.54 in non-VERA,
p=0.56).
Work ability
At the 12-month follow-up only 2.9% of the cohort, all
patients doing heavy manual works, had lost their working
place (data from Ancona and Rome).
Multivariate analysis
In the logistic regression analysis, having VERA (OR 2.02, 95%
CI 1.25 to 3.30) and being on DMARD within the 3rd month
(OR 1.65, 95% CI 1.06 to 2.55) emerged as predictors of DAS28
remission in the cohort of 481 RA patients (table 4).
DISCUSSION
Over the past few years, new data suggest that there are two
main modalities to reach the major outcomes in RA: early and
aggressive therapeutic approaches. However, the type and the
efﬁcacy of treatment is very much dependent on when the ther-
apies are given. The FinRaCo trial,3 15 16 showed that: a delay
in therapy (>4 months) was the only signiﬁcant predictor for
remission in patients treated with the single-DMARD strategy,
while no variable was a signiﬁcant predictor for remission in
those treated using the combination-DMARD strategy; at
2 years, 40% of patients in the combination-DMARD group
and 18% in the single-DMARD group achieved remission
(p<0.009), but at 5 years the difference between the groups dis-
appeared (28% and 22%). Therefore, the only way to avoid nega-
tive structural outcomes is to start the appropriate treatment
within 4 months.
In the present study, the mean percentage of remission
achieved in early RA patients from the three centres involved,
according to DAS28 criteria, was 34.3% (range 19.5–49%). This
remission rate is quite similar to that obtained for the groups
in the BeSt study (38–46% remission), but lower than other
tight control studies (ie, FIN-RACo, TICORA, CAMERA).3 17 18
It should be considered, however, that all these studies were ran-
domised controlled trials and included established treatment
protocols, while our study, being an observational study with
broad individual autonomy in the choice of therapeutic regimen,
may better reﬂect what happens in the real world of clinical
practice.
Another important issue concerns the factors that may affect
the achievement of remission. In the BeST trial, it was clearly
shown that even the worst prognostic factors (rheumatoid
factor, ACPA, shared epitope positivity) disappeared when
patients were treated aggressively and promptly.19 In the sub-
group treated conventionally, all these factors persisted as nega-
tive prognostic markers. The main conclusion could be that
only being aggressive in the therapeutic protocol can really lead
the majority of patients to reach major outcomes, but the
focus of these studies was on the therapeutic approach. In our
report, the major predictor of remission was to have VERA,
along with being on DMARD within 3 months from disease
onset. Certainly, the study presents some limitations, mainly
related to the variability of the patient baseline characteristics
and to the different management and therapeutic strategies in
the three centres. However, despite these differences, a
symptom duration of less than 12 weeks emerged as a deter-
minant of a really hard outcome such as remission. Moreover,
having obtained these data in the real world adds strength to
what has been seen recently in formal trials such as COMET,
which showed important better outcomes in patients treated
within 4 months from symptom onset.20
This ﬁnding is even more important because, unlike disease
activity, erosions and autoantibody positivity, VERA is a modi-
ﬁable factor through interventions on patient referral.
In a large cohort of early arthritis, van der Linden et al4
recently found that only 31% of patients were evaluated
within 12 weeks (the ‘window of opportunity’ period), yet the
delay greatly inﬂuenced the outcome in terms of x-ray progres-
sion, as well as in terms of persistent remission. In our study,
the percentage of RA patients seen within 12 weeks from
symptom onset ranged between 1% and 50%, reﬂecting what
was recently observed by Raza et al21 in 10 centres from eight
European countries. These results suggest that, to improve the
outcomes in RA patients further, an important challenge is to
ensure that patients with arthritis will be seen by a rheuma-
tologist as early as possible after symptom onset.
Our observational study in a real-life setting allowed us to
draw a clear-cut conclusion. The most important result is that
the percentage of patients, with all their comorbidities, that
can achieve remission is really high now. Despite the different
results in terms of major outcomes among the three early arth-
ritis clinics, starting therapy within 3 months’ disease duration
played the most important role, along with the early use of
DMARD to achieve remission. VERA thus seems to represent a
real window of opportunity, not only in terms of clinical out-
comes but also in terms of pharmacoeconomy. In fact, we
observed that patients with VERA achieve remission with a sig-
niﬁcantly lesser use of anti-TNF drugs compared with RA
patients with a symptom duration of more than 3 months.
This ﬁnding could enable savings to be made in pharmaco-
logical costs only by starting treatment as early as possible.
Moreover, as it has been established that the annual RA costs
have increased to €20 000 with a HAQ increase from 0.5 to 2,
and that decreasing HAQ from 1.5 to 0.5 means a gain of at
least US$4385 per year,22 the signiﬁcant decrease in HAQ
values obtained with an early intervention, and in particular in
VERA patients as seen in our study, appears to be cost saving.
Another important ﬁnding arising from this study is that
referral is really different in a small province and in a metropol-
itan area. We observed that, in the metropolitan area, the minor-
ity of patients arrived through their GPs and the majority from
Table 4 Model predicting 12-month DAS28 remission in the follow-up
cohort of 481 early RA patients with moderate–high disease activity at
baseline
Variables OR (95% CI)
DAS28 T0, <5.1=1 1.54 (0.94 to 2.51)
HAQ T0, <1.5=1 1.29 (0.75 to 2.23)
VERA, yes=1 2.03 (1.25 to 3.30)
Anti-CCP+, yes=1 1.39 (0.94 to 2.07)
Erosions T0, yes=1 0.47 (0.29 to 1.08)
DMARD within 3 months from disease onset, yes=1 1.65 (1.06 to 2.55)
Hosmer–Lemeshow test p=0.59
CCP, cyclic citrullinated protein; DAS28, disease activity score in 28 joints; DMARD,
disease-modifying antiheumatic drug; HAQ, health assessment questionnaire; T0,
baseline; VERA, very early rheumatoid arthritis.
Bold type indicates that the p value is less than 0.05.
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the call centre. The GPs seem to be really active in a small prov-
ince, where it can be easier to create a collaboration network
between the referral centre and the GPs, while the patient is
more prone to decide himself in a metropolitan area. For this
reason, in metropolitan areas, it seems appropriate to use the
media (eg, internet, newspaper, TV, brochures) to raise aware-
ness among the population, other than educating primary care
physicians.
The take-home message that arises remains: diagnose early
and treat to target within 12 weeks from symptom onset. The
recommendation of the EULAR committee stating that ‘Patients
presenting with arthritis of more than one joint should be
referred to and seen by a rheumatologist, ideally within 6 weeks
after the onset of symptoms’ remains of fundamental import-
ance and appears to be increasingly supported by evidence-based
data.23 In this setting, it is crucial to minimise the delay in
patient referral and interventions are required at all levels
(patients, physicians and health systems) to ensure timely treat-
ment for RA patients.
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